, hopes it can have as much success in drugs for hepatitis C as it has had in treating human immunodeficiency virus, or HIV.
Gilead was developing its own drug in the same category as PSI-7977, but
Gilead executives said Monday it wasn't performing as well in testing.
Gilead said it plans to finance the transaction with cash on hand, bank debt and senior unsecured notes, and expects to close the deal in the first quarter 2012.